Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
Analyzing the Most Promising Drugs That Will Lose Patent in the U...
Assessing the Growing Role & the Demand of Apps in Managing...
Insights Into the Key Advancements Transforming the Type 2 Diabet...
Evaluating the Major Developments in the Smart Pills Market
Emerging Market for Organ on a Chip

Search by Categories

Home / Blog / Endocrinology and metabolic disorders

Endocrinology and Metabolic Disorders

Olympus Launches New Gynecologic Power Morcella...

Olympus Launches New Gynecologic Power Morcellator for Its Contained Tissue Extraction System On November 30, 2022, Olympus, a global technology leader in designing and delivering innovative soluti...

Dec 08, 2022

MedTech News and Updates for Olympus, GE, Journey Biosciences, NeuroOne, Enovis
MedTech News Updates for AnchorDx, UroMems, NeuroLogica, Ypsomed
AnchorDx’s UriFind Bladder Cancer Assay in the US; UroMems Initiates Smart Implant to Treat Stress Urinary Incontinence; FDA 510(k) Clearance to NeuroLogica’s BodyTom 64; CE-IVD Mark Approval to SeekInCure’s Recurrence Monitoring Kit Gets; Ypsomed and CamDiab’s Automated Insulin Dosing System; Boston Scientific to Acquire Apollo Endosurgery

AnchorDx Clinical Trial Enrols First Patient for its UriFind® Bladder Cancer Assay in the US On November 23, 2022, AnchorDx, announced the first patient enrollment for its clinical trials of the UriFind® bladder cancer assay in the United States.  The UriFind® bladder cancer assay clinical trial in the U...

Find More
Pharma News Updates Merck, Regeneron, Provention, Ardelyx, AbbVie
FDA Approves Teplizumab to Delay the Onset of Type 1 Diabetes; FDA Backs Ardelyx’s CKD Therapy Xphozah; Merck to Acquire Imago BioSciences; Accelerated Approval to ImmunoGen’s ELAHERE; Regeneron and CytomX Announces Research Collaboration; FDA Grants Priority Review to Epcoritamab R/R LBCL

Merck to Acquire Imago BioSciences, Inc. for USD 1.35 Billion While its rumored acquisition of Seagen has yet to materialize, Merck & Co has continued to bolster its pipeline with smaller transactions, the most recent of which was a USD 1.35 billion agreement to acquire Imago BioSciences and its bomedemstat ...

Find More
gene-therapy-for-complex-diseases
Gene Therapy: The Next Milestone in Treating Complex Diseases

Gene therapy is an experimental technique that introduces functional genes into a patient’s body to counteract or replace defective ones, thereby curing disease without using pharmaceuticals, radiotherapy, or surgery. Genetic defects that are difficult to treat with drugs or antibodies can be treated with therapy w...

Find More

More Views & Analysis

MedTech News for Medtronic, Penumbra, and Genesis
Medtronic Launches Infusion Set for Insulin Pumps; Penumbra’s Virtual Reality-Based Rehabilitation System; FDA Approval to Genesis’s Chocolate Touch® Drug-coated Balloon PTA Catheter; FDA Nod to AEYE’s AI-based Autonomous Screening; Alpheus Medical Treats First High-Grade Glioma Brain Cancer Patient with its Proprietary Platform; Karidum’s Next Generation Globe® Pulsed Field System

Medtronic Launches World's First and Only Infusion Set for Insulin Pumps that Doubles Wear Time up to 7 days in the US  On November 15, 2022, Medtronic plc, a global leader in healthcare technology, announced the US launch of the Medtronic Extended infusion set, the first and only infusion set labeled for up to ...

Find More
Innovation and Advances in Type 2 Diabetes Treatment and Management
Insights Into the Key Advancements Transforming the Type 2 Diabetes Treatment and Management

Diabetes is a chronic metabolic disorder that is influenced by a wide variety of factors and is characterized by high or low blood glucose (or blood sugar) levels in the body. Diabetes is a major risk factor for blindness, kidney failure, heart attacks, stroke, and lower limb amputation. Also, it can significantly ...

Find More
MedTech News for Enspectra, Mentice, and EndoStim
FDA Approval to DePuy TELIGEN System; FDA Breakthrough Device Designation for the EndoStim System; GE and Accuray Announces Collaboration; Mentice and Acandis Announces a Three-Year Agreement; Indigo Diabetes Enrolled First Participant in the Shine Clinical Trial; FDA IDE Approval to MedAlliance’s SELUTION SLR

DePuy Synthes Received FDA Approval for TELIGEN™ System  On October 20, 2022, DePuy Synthes, The Orthopaedics Company of Johnson & Johnson, provides one of the most comprehensive orthopedics portfolios in the world that helps heal and restore movement for the millions of patients, announced that ...

Find More
MedTech Updates for Neuspera, Abbott, and ZEISS,
Neuspera Medical’s Nuvella System; Abbott Presented the Data for FreeStyle Libre 2 System; ZEISS Receives FDA 510(k) Clearance for MTLawton; FDA 510(k) Clearance for the GHOST 3D-Printed Titanium Spacer System; Thermo Fisher Scientific Launched CE-IVD Marked TaqPath Enteric Bacterial Select Panel; BIOCORP and Merck Announced New Partnership

Neuspera Medical Announces First Successful Implant of the Nuvella™ System in the Second Phase of Its Sans-Uui Ide Clinical Trial On October 10, 2022, Neuspera Medical, a medical device company involved in the development of implantable devices for patients suffering from chronic illnesses, announced that...

Find More
MedTech News for Olympus and Fujifilm
Olympus’s THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device; Merit Medical’s TEMNO Elite; Thermo Fisher Scientific’s Oncomine Dx Target Test; Fujifilm Latest Generation Endoscopic Ultrasound; Indigo Diabetes’s Shine Clinical Trial; Cala Health Published Data for its TAPS Therapy

Olympus Launched THUNDERBEAT Open Fine Jaw Type X Surgical Energy Device On September 28, 2022, Olympus Corporation (Olympus), a global MedTech company, announced the release of the THUNDERBEAT™ Open Fine Jaw Type X surgical energy devices for open surgery. The device THUNDERBEAT Open Fine Jaw Type X surg...

Find More
Pharma News and Updates for Akero Chiesi Pfizer
AstraZeneca’s Danicopan Trial; CHMP Recommends Sanofi/AstraZeneca’s nirsevimab; Akero’s NASH Drug Trial; FDA Grants Orphan Drug Status to SY-5609; BMS’s Opdivo Trial Results; Pfizer to File for FDA Approval for Meningitis Vaccine; EMA Orphan Drug Designation to CAN-2409; FDA Starts Priority Review of Chiesi ‘s velmanase alfa

AstraZeneca’s Danicopan Shows Positive Results in Phase III Trial Danicopan, an oral Factor D inhibitor developed by AstraZeneca, was expected to fail a phase II trial in rare kidney disease in 2020, but a new readout could revive the drug. Danicopan (ALXN2040) has demonstrated efficacy as an adjunct treatment f...

Find More

Rheumatoid Arthritis
Rheumatoid Arthritis...

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More
Toll-like receptors (TLR) 7 and 8 Agonist
Toll-like receptors (TLR)...

Toll-like receptors (TLR) 7 and 8 are functionally localized to endosomes and recognize specific RNA.....

Find More
Gene Therapies
Gene Therapies

Gene therapies are regarded as one of the potential revolution in the Pharmaceutical field and Healt.....

Find More